Scientists have identified pantethine, a readily available derivative of vitamin B5, as a potential treatment for psoriasis after it demonstrated the ability to calm overactive immune cells. In laboratory studies, the supplement prevented the onset of psoriasis in mice, while a small human trial produced promising results. The findings, reported in the health category, suggest an unexpected biological link between cholesterol metabolism and autoimmune inflammation, offering a possible new avenue for managing a condition that affects millions worldwide.
Researchers caution that the human trial was limited in scale and that further clinical investigation is needed before pantethine can be recommended as a standard therapy. Nonetheless, the discovery is notable because pantethine is already commercially available as a dietary supplement, potentially accelerating future research and accessibility. The study authors say the results warrant larger trials to confirm efficacy and safety in patients with psoriasis, a chronic skin disorder driven by immune system dysfunction.
Independent reporting synthesized from primary wires and global correspondents.